Literature DB >> 23708011

Sulphonamido-quinoxalines: search for anticancer agent.

Rahul Ingle1, Rajendra Marathe, Dipak Magar, Harun M Patel, Sanjay J Surana.   

Abstract

A series of new sulphonamido-quinoxaline derivatives 3(a-p) have been prepared which are structurally similar to the High Throughput Screening (HTS) hit identified by Porter and collaborator. The newly synthesized compounds 3b, 3c, 3f, 3i, 3j, 3l, 3n and 3o were further evaluated in the National Cancer Institute for in vitro cytotoxicity assay among them compound 3l showed highest activity against Leukemia RPMI-8226 cell lines (GI50: 1.11 μM) as compared to other tested compounds. It is to be noted that compound 3l shows significant activity (GI50: 1.11 μM) compared to the High Throughput Screening (HTS) hit identified by Porter and collaborator (IC50 = 1.3 μM). Further docking study confirms the c-Met kinase inhibitory mechanism of the synthesized compounds.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer; Docking; Lipinski's rule; Synthesis sulphonamido-quinoxaline

Mesh:

Substances:

Year:  2013        PMID: 23708011     DOI: 10.1016/j.ejmech.2013.04.028

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

1.  Apoptotic impact on Brugia malayi by sulphonamido-quinoxaline: search for a novel therapeutic rationale.

Authors:  Priyanka S Bhoj; Rahul G Ingle; Kalyan Goswami; Lingaraj Jena; Shailesh Wadher
Journal:  Parasitol Res       Date:  2018-03-23       Impact factor: 2.289

2.  Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.

Authors:  Georg Haymerle; Dietmar Thurnher; Lorenz Kadletz; Isabella Stanisz; Markus Brunner; Ulana Kotowski; Elisabeth Enzenhofer; Gregor Heiduschka
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-29       Impact factor: 2.503

3.  DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway.

Authors:  Joo-Young Im; Bo-Kyung Kim; Sung-Hoon Yoon; Byoung Chul Cho; Yu Mi Baek; Mi-Jung Kang; Nayeon Kim; Young-Dae Gong; Misun Won
Journal:  Exp Mol Med       Date:  2021-04-15       Impact factor: 8.718

4.  Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.

Authors:  Mohamed Alswah; Ashraf H Bayoumi; Kamal Elgamal; Ahmed Elmorsy; Saleh Ihmaid; Hany E A Ahmed
Journal:  Molecules       Date:  2017-12-27       Impact factor: 4.411

5.  Synthesis of novel, DNA binding heterocyclic dehydroabietylamine derivatives as potential antiproliferative and apoptosis-inducing agents.

Authors:  Fengyi Zhao; Xu Sun; Wen Lu; Li Xu; Jiuzhou Shi; Shilong Yang; Mengyi Zhou; Fan Su; Feng Lin; Fuliang Cao
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

6.  Convenient Synthesis and Anticancer Activity of Methyl 2-[3-(3-Phenyl-quinoxalin-2-ylsulfanyl)propanamido]alkanoates and N-Alkyl 3-((3-Phenyl-quinoxalin-2-yl)sulfanyl)propanamides.

Authors:  Samir M El Rayes; Ahmed Aboelmagd; Mohamed S Gomaa; Ibrahim A I Ali; Walid Fathalla; Faheem H Pottoo; Firdos A Khan
Journal:  ACS Omega       Date:  2019-10-28

Review 7.  Recent advances in the transition-metal-free synthesis of quinoxalines.

Authors:  Biplob Borah; L Raju Chowhan
Journal:  RSC Adv       Date:  2021-11-19       Impact factor: 4.036

8.  A Convenient Way to Quinoxaline Derivatives through the Reaction of 2-(3-Oxoindolin-2-yl)-2-phenylacetonitriles with Benzene-1,2-diamines.

Authors:  Alexander V Aksenov; Nikolai A Arutiunov; Dmitrii A Aksenov; Artem V Samovolov; Igor A Kurenkov; Nicolai A Aksenov; Elena A Aleksandrova; Daria S Momotova; Michael Rubin
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

9.  Convenient Synthesis of N-Alkyl-2-(3-phenyl-quinoxalin-2-ylsulfanyl)acetamides and Methyl-2-[2-(3-phenyl-quinoxalin-2-ylsulfanyl)acetylamino]alkanoates.

Authors:  Samir Mohamed El Rayes; Gaber El-Enany; Mohamed Sayed Gomaa; Ibrahim A I Ali; Walid Fathalla; Faheem Hyder Pottoo; Firdos Alam Khan
Journal:  ACS Omega       Date:  2022-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.